Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.35 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.32 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.31 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.31 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.30 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.30 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | PDE6D | O43924 | 1/20 | 0.31 |
| ▸ | PDE6A | P16499 | 1/20 | 0.31 |
| ▸ | PDE6G | P18545 | 1/20 | 0.31 |
| ▸ | PDE6B | P35913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1925400 | 1.00 | MEN1 (0.38) | MEN1KMT2ASRCBRD4BRD9 | |
| SCHEMBL1924717 | 0.99 | MEN1 (0.38) | MEN1KMT2ASRCBRD4BRD9 | |
| SCHEMBL1924719 | 0.99 | MEN1 (0.38) | MEN1KMT2ASRCBRD4BRD9 | |
| Hydrochloric Acid SCHEMBL1925719 | 0.92 | MAPT (0.35) | MEN1KMT2ABRD4BRD9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1925716 | 0.92 | MAPT (0.35) | MEN1KMT2ABRD4BRD9ALDH1A1 | |
| SCHEMBL1926291 | 0.91 | MAPT (0.35) | MEN1KMT2ABRD4BRD9ALDH1A1 | |
| SCHEMBL1926292 | 0.91 | MAPT (0.35) | MEN1KMT2ABRD4BRD9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1926864 | 0.89 | MEN1 (0.38) | MEN1KMT2ASRCHDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL27535235 | 0.89 | MEN1 (0.35) | MEN1KMT2AHDAC1HDAC2PIK3CD | |
| Hydrochloric Acid SCHEMBL27535238 | 0.89 | MEN1 (0.35) | MEN1KMT2AHDAC1HDAC2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1431293-B1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2011-06-08 | — | — | EP | disclosed |
| US-7211577-B2 | Water-soluble phenylpyridazine derivative and medicine containing the same | KOWA CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7087606-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | KOWA CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| EP-1604984-A1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVE AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20050085480-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| US-6869954-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-6861428-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| EP-1431293-A1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
| US-20030119838-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | IL1B, IL1A, IL1R1 | SRC 2858/4885HDAC1 157/4885HDAC2 284/4885 |
| US-20030119838-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | SRC 3764/4885HDAC1 536/4885HDAC2 1700/4885 |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | SRC 3741/4885HDAC1 607/4885HDAC2 1722/4885 |
| US-20050085480-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | SRC 4159/4885HDAC1 318/4885HDAC2 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.